echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > East Sunshine Pharmaceuticals" phosphoric acid oseltamivir dry suspension agent reported to the market.

    East Sunshine Pharmaceuticals" phosphoric acid oseltamivir dry suspension agent reported to the market.

    • Last Update: 2020-08-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On June 29, CDE's official website showed that Dongsun Pharmaceuticals, a class 3 generic drug called "Oseltamico co-suspension agent phosphate", was listed as the third domestic company to report the dosage form.
    Oseltamivir is a specific inhibitor that acts on neuraminidase and inhibits the degeneration of mature influenza viruses from host cells, thereby inhibiting the spread of influenza viruses in the human body to act as a treatment for influenza.
    oseltamivir's original research manufacturer is Roche, the product is called Duffy, in 2001 Oseltamivir capsules were approved in China;
    in 2005 and 2006, Roche licensed Oseltamivir to Shanghai Sino-Western 3D Pharmaceuticals and Dongsun Pharmaceuticals for production, with the commodity names "Orfie" and "Kwi" listed for sale respectively.
    and the production of three-dimensional pharmaceutical industry in China and the West oseltamivir as a government procurement drug, is not in circulation in the market, so the current domestic Oseltamivir market East Sunshine a large.
    East Sunshine Pharmaceuticals' 2019 financial results show that total sales of Kwiat particles and cove capsules reached 5.93 billion yuan, accounting for 95.33 percent of the company's total turnover.
    , the granule is the exclusive dosage form of Dongsun medicine, was approved for listing in 2008, the current market granule form only East Sunshine drug one obtained the production approval, patent protection period until 2026.
    sales of Kwiat particles in 2019 were well higher than the 4.27 billion yuan in capsules and 1.66 billion yuan for capsules.
    Insight database, Cinda Pharma (a subsidiary of Berry Pharmaceuticals) filed a listing application for Class 4 generics of Oseltamiel Capsules as early as December 2019 and is currently under review.
    March 21, 2020, Xintai Pharmaceuticals oselavir dry suspension agent reported to the market, for the dosage form of the first domestic;
    prior to Cinda Pharmaceuticals, already had Alvogen, Hetero's imported oseltamigo coin in domestic reports and is currently under review.
    at present, oseltamivir capsules in addition to the shanghai West-West three-dimensional, Dongsun, Roche has been approved for listing, has Xintai Pharmaceutical, Chengdu Bent, Stone Pharmaceutical Group 4 newspapers listed;
    however, in terms of raw materials, the current domestic only Yichang Dong Sunshine Changjiang Pharmaceutical, Shanghai China and the West three-dimensional to get the production approval, but the three-dimensional Chinese and Western have expired, only the East Sunshine's code in use;
    from the supply of raw materials, The East Sunshine medicine still has its own advantages.
    picture source: Insight database () Currently, Oseltamivir this heavy-selling variety of nearly 6 billion yuan is about to usher in a strong rival, but The East Sunshine's exclusive granulated type is still the best-selling and no competition, but dry mixer selling agent after being approved for the market may be its biggest threat;
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.